quinidine has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demircan, T; Yavuz, M | 1 |
| Abad, A; Antón, A; Aranda, E; Ariza, A; Blanco, E; Carrato, A; Cervantes, A; Dorta, J; Garcia de Paredes, ML; Massuti, B; Maurel, J; Vicent, JM | 1 |
1 trial(s) available for quinidine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quinidine; Survival Analysis; Tumor Suppressor Protein p53 | 1998 |
1 other study(ies) available for quinidine and Pancreatic Neoplasms
| Article | Year |
|---|---|
A potent ion channel blocker, hydroquinidine, exhibits strong anti-cancer activity on colon, pancreatic, and hepatocellular cancer cells.
Topics: Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Colon; Humans; Liver Neoplasms; Pancreatic Neoplasms; Quinidine | 2023 |